Kestra Advisory Services LLC Buys 4,377 Shares of Boston Scientific Co. (NYSE:BSX)

Kestra Advisory Services LLC increased its position in shares of Boston Scientific Co. (NYSE:BSX) by 1.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 257,085 shares of the medical equipment provider’s stock after purchasing an additional 4,377 shares during the period. Kestra Advisory Services LLC’s holdings in Boston Scientific were worth $17,608,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Mutual Advisors LLC boosted its stake in shares of Boston Scientific by 20.7% in the fourth quarter. Mutual Advisors LLC now owns 5,999 shares of the medical equipment provider’s stock worth $347,000 after acquiring an additional 1,029 shares during the period. Raymond James Financial Services Advisors Inc. grew its stake in Boston Scientific by 3.0% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 507,550 shares of the medical equipment provider’s stock worth $29,341,000 after acquiring an additional 14,723 shares in the last quarter. Pacer Advisors Inc. grew its stake in Boston Scientific by 79.6% in the 4th quarter. Pacer Advisors Inc. now owns 178,639 shares of the medical equipment provider’s stock worth $10,327,000 after acquiring an additional 79,168 shares in the last quarter. WASHINGTON TRUST Co raised its stake in shares of Boston Scientific by 320.9% during the fourth quarter. WASHINGTON TRUST Co now owns 8,418 shares of the medical equipment provider’s stock valued at $487,000 after acquiring an additional 6,418 shares in the last quarter. Finally, Ritholtz Wealth Management boosted its holdings in shares of Boston Scientific by 5.9% in the fourth quarter. Ritholtz Wealth Management now owns 21,855 shares of the medical equipment provider’s stock valued at $1,263,000 after purchasing an additional 1,208 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In related news, Director Charles J. Dockendorff sold 3,946 shares of the company’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $72.70, for a total value of $286,874.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Charles J. Dockendorff sold 3,946 shares of the business’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $72.70, for a total transaction of $286,874.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $77.30, for a total value of $539,785.90. Following the sale, the executive vice president now owns 42,908 shares of the company’s stock, valued at $3,316,788.40. The disclosure for this sale can be found here. Insiders have sold 62,441 shares of company stock valued at $4,624,453 in the last 90 days. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Stock Performance

NYSE BSX traded up $0.66 during trading hours on Friday, reaching $74.92. The stock had a trading volume of 7,973,424 shares, compared to its average volume of 5,863,226. Boston Scientific Co. has a 52-week low of $48.35 and a 52-week high of $79.43. The stock has a fifty day moving average of $76.49 and a 200 day moving average of $70.40. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.14 and a current ratio of 1.66. The stock has a market cap of $109.92 billion, a P/E ratio of 62.96, a price-to-earnings-growth ratio of 2.49 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.62 EPS for the quarter, beating the consensus estimate of $0.58 by $0.04. Boston Scientific had a net margin of 12.00% and a return on equity of 16.80%. The business had revenue of $4.12 billion for the quarter, compared to the consensus estimate of $4.02 billion. During the same period in the prior year, the firm earned $0.53 EPS. The business’s revenue for the quarter was up 14.5% on a year-over-year basis. Sell-side analysts predict that Boston Scientific Co. will post 2.4 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on BSX. JPMorgan Chase & Co. increased their price target on Boston Scientific from $82.00 to $85.00 and gave the stock an “overweight” rating in a research report on Thursday. Raymond James raised their target price on shares of Boston Scientific from $85.00 to $91.00 and gave the company a “strong-buy” rating in a research report on Thursday. UBS Group upped their price target on shares of Boston Scientific from $74.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, April 25th. Wells Fargo & Company lifted their price objective on shares of Boston Scientific from $72.00 to $82.00 and gave the company an “overweight” rating in a report on Thursday, April 25th. Finally, Canaccord Genuity Group lifted their price target on Boston Scientific from $83.00 to $88.00 and gave the company a “buy” rating in a report on Thursday. Two research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and an average target price of $84.76.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.